Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Lantern Pharma and its subsidiary Starlight Therapeutics presented new preclinical data and Phase 1b trial design for LP-184 (STAR-001) in glioblastoma at SNO 2024. The data shows LP-184 combined with spironolactone increases GBM cell sensitivity up to 6-fold through ERCC3 degradation. The drug demonstrates favorable brain penetrance and effectiveness in temozolomide-resistant GBM models. Currently in Phase 1a trials, LP-184 has shown no dose-limiting toxicities across nine patient cohorts. The planned Phase 1b trial will evaluate LP-184 as both monotherapy and in combination with spironolactone in patients with IDH wild type GBM at first progression.
Lantern Pharma (NASDAQ: LTRN) has announced the first patient dosing in Japan for its Phase 2 HARMONIC™ clinical trial of LP-300 in never-smoker NSCLC patients. The trial, now expanded to ten sites across Japan and Taiwan, focuses on patients who have progressed after TKI treatment. Initial results from the U.S. trial showed an 86% clinical benefit rate and 43% objective response rate among the first seven patients. The expansion is significant as NSCLC in never-smokers occurs 2-3 times more frequently in East Asian countries, with Japan reporting 33-40% of new lung cancer cases in never-smokers.
Lantern Pharma reported Q3 2024 financial results and clinical updates. The company's LP-300 Harmonic™ Trial showed an 86% clinical benefit rate in initial patients and expanded to Japan and Taiwan. Phase 1 trials for LP-184 and LP-284 continue with no dose-limiting toxicities. LP-184 received FDA Fast Track Designation for Glioblastoma. Financial highlights include $28.1 million in cash and equivalents, R&D expenses of $3.7 million, and a net loss of $4.5 million ($0.42 per share). The company maintains three active clinical trials and is advancing its AI-guided precision-oncology drug candidates.
Starlight Therapeutics, a subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), announced the formation of its Scientific Advisory Board (SAB) to support the development of STAR-001 for CNS and brain tumors. The inaugural SAB includes four distinguished experts: Dr. Mitchel S. Berger from UCSF, Dr. Lisa M. DeAngelis from Memorial Sloan Kettering, Dr. Stuart Grossman from Johns Hopkins Kimmel Cancer Center, and Dr. John Laterra from Johns Hopkins. These experts will provide strategic guidance for developing treatments targeting both adult and pediatric CNS cancers.
Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer therapy development company, will host its third quarter 2024 operating and financial results webcast on Thursday, November 7, at 4:30 p.m. ET. CEO Panna Sharma and management will discuss Q3 2024 results ending September 30, provide guidance on upcoming milestones, clinical trials, and developments of their proprietary RADR® AI and machine learning platform. A replay will be available on the company's investor relations website after the call.
Lantern Pharma (NASDAQ: LTRN), an AI-focused company developing cancer therapies, announced its participation in the upcoming ThinkEquity Conference. The presentation is scheduled for Wednesday, October 30, 2024, at 10:30 a.m. ET and will take place at the Mandarin Oriental in New York, NY. The company's management will be available for one-on-one meetings during the conference. The event can be accessed through provided webcast and registration links, offering investors an opportunity to learn about Lantern's innovative approach to oncology drug discovery and development.
Lantern Pharma (NASDAQ: LTRN), an AI-focused oncology drug development company, announced two public webinars in October. The first, on October 28th, features CEO Panna Sharma discussing AI's role in developing therapies for brain and childhood cancers. The second, on October 30th, hosts Actuate Therapeutics' COO Andrew Mazar, highlighting how Lantern's AI platform accelerated the development of Actuate's drug candidate, Elragllusib.
The webinars will showcase RADR®, Lantern's AI platform, and its impact on advancing their portfolio and collaborators' work. Lantern will detail how big data and AI are leveraged to develop LP-184 and LP-284, currently in Phase 1 trials. The company will also discuss their blood-brain-barrier penetrability algorithm, important for LP-184's development in CNS cancer indications, including glioblastoma.
Lantern Pharma has received four Rare Pediatric Disease Designations and the FDA's Fast Track Designation for glioblastoma, underlining their progress in addressing critical unmet needs in oncology.
Lantern Pharma's investigational drug-candidate, LP-184, has received Fast Track Designation from the FDA for the treatment of Glioblastoma (GBM). This designation is designed to expedite FDA review of important new drugs for serious conditions with unmet medical needs. GBM affects over 13,000 U.S. adults annually and approximately 300,000 globally. LP-184, to be developed as STAR-001 by Starlight Therapeutics (a Lantern Pharma subsidiary), has the potential to be the first new GBM drug in over 20 years.
LP-184 is currently in a Phase 1A clinical trial evaluating its safety and tolerability in various solid tumors, including GBM. The drug was optimized using Lantern's AI platform, RADR®, which has over 100 billion data points and aids in cancer therapy discovery and development. A Phase 1b/2a clinical trial for recurrent GBM is targeted to start in late 2024/early 2025.
Lantern Pharma (NASDAQ: LTRN) has received three rare pediatric disease designations (RPDD) from the FDA for its drug candidate LP-184 in malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma. This brings the total RPDDs for LP-184 to four, including a previous designation for atypical teratoid rhabdoid tumors. The efficacy of LP-184 was demonstrated through tumor regression and extended event-free survival in models developed by the NCI-supported Pediatric Preclinical Testing Program.
RPDDs can lead to Priority Review Vouchers upon FDA marketing approval, which can expedite future drug reviews or be sold for significant sums. LP-184 is currently in a Phase 1A clinical trial enrolling 50-60 patients across various solid tumors. Lantern Pharma aims to use AI and data-driven approaches to revolutionize cancer drug development, potentially reducing costs and accelerating timelines for new therapies.
Lantern Pharma (NASDAQ: LTRN) reported Q2 2024 financial results and business updates. Key highlights include:
1. Preliminary data from LP-300 Harmonic™ Trial showed 86% clinical benefit rate in initial 7-patient cohort.
2. Phase 1 trials for LP-184 and LP-284 progressing with no dose-limiting toxicities.
3. Launched AI-driven collaboration with Oregon Therapeutics for XCE853 development.
4. Starlight Therapeutics advancing Phase 1B/2 trial for STAR-001 in recurrent GBM.
5. Q2 2024 financials: $33.3M cash position, $3.9M R&D expenses, $1.5M G&A expenses, $4.96M net loss ($0.46 per share).
6. RADR® AI platform continues to expand in size and capabilities.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
